Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results

We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Immunovant Inc. (NASDAQ:IMVT) is one of the best-performing stocks on Thursday.

Immunovant grew by 14.64 percent on Thursday to close at $24.82 apiece as investors gobbled up its shares ahead of the results of its third quarter earnings performance in the next few days.

According to Immunovant Inc. (NASDAQ:IMVT), it is set to announce the results of its financial and operating highlights before market open on November 10, 2025. A conference call will be held to elaborate on the results.

In the second quarter of the year, the company widened its net loss by 38 percent to $120.6 million from $87.15 million in the same period last year, as total operating expenses grew by 35 percent to $127 million from $94 million year-on-year.

In other developments, traders also may have positioned their portfolios following unconfirmed buzz that Immunovant Inc. (NASDAQ:IMVT) is set to be acquired by one of its largest shareholders, Roivant Sciences Ltd.

While we acknowledge the potential of IMVT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.